ORMP (Oramed Pharmaceuticals) 10-Year Sharpe Ratio: 0.32 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORMP Oramed Pharmaceuticals Inc ORMP
34 GF Score
Price $4.98
! 4 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals 10-Year Sharpe Ratio?

Oramed Pharmaceuticals ORMP -0.70% 34 10-Year Sharpe Ratio is 0.32 as of Sep. 09, 2026. GuruFocus rates ORMP with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-09-09), Oramed Pharmaceuticals's 10-Year Sharpe Ratio is 0.32.

Oramed Pharmaceuticals  (NAS:ORMP) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Oramed Pharmaceuticals 10-Year Sharpe Ratio Related Terms

ORMP vs IMUX, ABOS, ANTX: 10-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oramed Pharmaceuticals 10-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's 10-Year Sharpe Ratio falls into.


ORMP
34GF Score
Oramed Pharmaceuticals Inc ORMP
10-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Frequently Asked Questions Learn more about 10-Year Sharpe Ratio →
What does a 10-Year Sharpe Ratio of 0.32 mean?
Oramed Pharmaceuticals (ORMP) has a 10-Year Sharpe Ratio of 0.32 as of Sep. 09, 2026. 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. View historical data for Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' 10-Year Sharpe Ratio too high?
Oramed Pharmaceuticals' current 10-Year Sharpe Ratio is 0.32. Overall, Oramed Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' 10-Year Sharpe Ratio compare to IMUX and ABOS?
Oramed Pharmaceuticals' 10-Year Sharpe Ratio of 0.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Sharpe Ratio for a Biotechnology company?
A good 10-Year Sharpe Ratio depends on the Biotechnology industry context. However, 10-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Sharpe Ratio mean?
A high 10-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. View historical data for Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current 10-Year Sharpe Ratio is 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (ORMP) has a current 10-Year Sharpe Ratio of 0.32. The current 10-Year Sharpe Ratio is 0.32. Oramed Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Sharpe Ratio calculated?
10-Year Sharpe Ratio is calculated from a company's financial statements. For Oramed Pharmaceuticals (ORMP), the current 10-Year Sharpe Ratio is 0.32 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Other Exchanges ORMP:IsraelOJU1:Germany
Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
34GF Score

Get the complete analysis for ORMP

10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.98
Price